Journal: Frontiers in Medicine

Article Title: Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells

doi: 10.3389/fmed.2025.1643506

Figure Lengend Snippet: Dysregulation of miR-143/JNK/p-Bcl2-Beclin1 axis in abiraterone acetate-resistant prostate cancer cells. (A) PC3, abiraterone acetate-resistant PC3 (PC3-AbiR), (B) DU145 and abiraterone acetate-resistant DU145 (DU145-AbiR) cells were incubated with indicated increasing concentrations of abiraterone acetate for 24 h, followed by CCK-8 assay to assess the cell viability. (C) DU145, DU145-AbiR, and (D) PC3 and PC3-AbiR were prepared for qRT-PCR to assess the expression of miR-143. (E) PC3, PC3-AbiR, DU145 and DU145-AbiR cells were lysed for Western blot to assess the protein levels of p-JNK, p-Bcl2 and Beclin1, and (F–K) the optical density analyses were also measured. GAPDH was used as a loading control. Data were presented as the mean ± SD of three independent experiments. ** p < 0.01, **** p < 0.0001.

Article Snippet: Human prostate cancer cell lines PC3 and DU145 were obtained from ATCC (Manassas, VA, USA), and they were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Beyotime, Shanghai, China; Cat. No. C0222).

Techniques: Incubation, CCK-8 Assay, Quantitative RT-PCR, Expressing, Western Blot, Control

Journal: Frontiers in Medicine

Article Title: Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells

doi: 10.3389/fmed.2025.1643506

Figure Lengend Snippet: miR-143 modulates JNK/p-Bcl2-Beclin1 axis in abiraterone acetate-resistant prostate cancer cells. The miR-143 mimics, miR-143 inhibitor and corresponding control (NC) were respectively transfected into PC3-AbiR cells for 48 h. (A) The cells were then lysed for Western blot to assess the expression of p-JNK, p-Bcl2, Beclin1 and GAPDH, and (B–G) the optical density analyses were also measured. (H) PC3-AbiR cells transfected with NC or miR-143 mimics were incubated with vehicle or 5 ng/ml JNK agonist Anisomycin (ANI) for 24 h, followed by co-immunoprecipitation to assess the binding of p-Bcl2 and Beclin1 complex. IP, immunoprecipitation. IB, immunoblotting. Data were presented as the mean ± SD of three independent experiments. ** p < 0.01, *** p < 0.001.

Article Snippet: Human prostate cancer cell lines PC3 and DU145 were obtained from ATCC (Manassas, VA, USA), and they were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Beyotime, Shanghai, China; Cat. No. C0222).

Techniques: Control, Transfection, Western Blot, Expressing, Incubation, Immunoprecipitation, Binding Assay

Journal: Frontiers in Medicine

Article Title: Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells

doi: 10.3389/fmed.2025.1643506

Figure Lengend Snippet: Qiling decoction (QLD) enhances the effects of abiraterone acetate on modulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells. (A) PC3-AbiR and (B) DU145-AbiR cells were incubated with 10 mg/mL Qiling decoction (QLD) or 5 μM abiraterone acetate (Abi) for 24 h, followed by CCK-8 assay to assess cell viability. (C,D) Above cells were also prepared for qRT-PCR to assess the expression of miR-143. Data were presented as the mean ± SD of three independent experiments. *** p < 0.001.

Article Snippet: Human prostate cancer cell lines PC3 and DU145 were obtained from ATCC (Manassas, VA, USA), and they were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Beyotime, Shanghai, China; Cat. No. C0222).

Techniques: Expressing, Incubation, CCK-8 Assay, Quantitative RT-PCR

Journal: Frontiers in Medicine

Article Title: Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells

doi: 10.3389/fmed.2025.1643506

Figure Lengend Snippet: Qiling decoction (QLD) enhances the effects of abiraterone acetate on modulating JNK/p-Bcl2-Beclin1 axis in abiraterone acetate-resistant prostate cancer cells. PC3-AbiR cells were incubated with 10 mg/mL Qiling decoction (QLD) or 5 μM abiraterone acetate (Abi) for 24 h, followed by panel (A) Western blot to assess the protein levels of p-JNK, p-Bcl2 and Beclin1, and (B) the optical density analyses were also measured (B–D). GAPDH was used as a loading control. PC3-AbiR cells were incubated with 10 mg/mL QLD or 5 μM Abi for 24 h, followed by panel (E) co-immunoprecipitation to assess the binding of p-Bcl2 and Beclin1 complex, and (F) the optical density analyses were also measured. IP, immunoprecipitation. IB, immunoblotting. Data were presented as the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01.

Article Snippet: Human prostate cancer cell lines PC3 and DU145 were obtained from ATCC (Manassas, VA, USA), and they were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Beyotime, Shanghai, China; Cat. No. C0222).

Techniques: Incubation, Western Blot, Control, Immunoprecipitation, Binding Assay

Journal: Frontiers in Medicine

Article Title: Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells

doi: 10.3389/fmed.2025.1643506

Figure Lengend Snippet: Inhibiting miR-143 abolishes the effects of QLD in abiraterone acetate-resistant prostate cancer cells. (A) PC3-AbiR and (B) DU145-AbiR cells were transfected with miR-143 inhibitor or normal control (NC) for 24 h, followed by qRT-PCR to assess the expression of miR-143. (C) PC3-AbiR and (D) DU145-AbiR cells transfected with NC or miR-143 inhibitor were incubated with 10 mg/mL QLD or 5 μM abiraterone acetate (Abi) for 24 h, followed by CCK-8 assay. PC3-AbiR cells transfected with NC or miR-143 inhibitor were incubated with 10 mg/mL QLD or 5 μM Abi for 24 h, followed by panel (E) co-immunoprecipitation to assess the binding of p-Bcl2 and Beclin1 complex, and (F) the optical density analyses were also measured. (G) The mechanism diagram illustrating how QLD induces prostate cancer (PC) cells to overcome abiraterone resistance. Data were presented as the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Human prostate cancer cell lines PC3 and DU145 were obtained from ATCC (Manassas, VA, USA), and they were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Beyotime, Shanghai, China; Cat. No. C0222).

Techniques: Transfection, Control, Quantitative RT-PCR, Expressing, Incubation, CCK-8 Assay, Immunoprecipitation, Binding Assay